INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Announces Presentations at Upcoming Investment Conference Meetings
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 2, 2015-- NantKwest Inc. (Nasdaq:NK) today announced that the company will be presenting at the following upcoming investment conferences in November and December: Citi 2015 Global Healthcare Conference, Jefferies 2015 Global Healthcare Conference and the
View HTML
Toggle Summary NantKwest Continues the Strengthening of Its Leadership Team and Appoints a Seasoned Bioprocessing Manufacturing Executive
Stephen Farrand , Ph.D., former Merck executive appointed Senior Vice President Global Manufacturing CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 6, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using
View HTML
Toggle Summary NantKwest Augments, Strengthens Senior Management Team
-- Company Adds Clinical Development , Medical Affairs and M&A Executives -- CULVER CITY, Calif. --(BUSINESS WIRE)--Sep. 22, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to
View HTML
Toggle Summary NantKwest Announces Prostate Cancer Foundation $1 Million Challenge Award to Study a Novel Natural Killer Cell Therapy in Prostate Cancer
LOS ANGELES --(BUSINESS WIRE)--Aug. 26, 2015-- NantKwest (Nasdaq:NK), working with Ganesh Palapattu, MD and his team at the University of Michigan , along with Karen Knudsen , PhD and her group at Thomas Jefferson University , announced a $1 Million Challenge award from the Prostate Cancer
View HTML
Toggle Summary NantKwest Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CULVER CITY, Calif. --(BUSINESS WIRE)--Jul. 31, 2015-- NantKwest, Inc. (formerly Conkwest, Inc. ) (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Pricing of Initial Public Offering
CULVER CITY, Calif.--( BUSINESS WIRE )--NantKwest, Inc. (formerly Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced today the
View HTML
Toggle Summary NantKwest Announces Launch of Initial Public Offering
CULVER CITY, Calif.--( BUSINESS WIRE )--NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the Natural Killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases, today
View HTML
Toggle Summary Conkwest Files Registration Statement for Proposed Initial Public Offering
CARDIFF-BY-THE-SEA, Calif.--( BUSINESS WIRE )--Conkwest, Inc., a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, today announced that it has publicly
View HTML
Toggle Summary Conkwest, Sorrento and NantWorks Announce Presentation at the 33rd Annual J. P. Morgan Healthcare Conference by Dr. Patrick Soon-Shiong
SAN DIEGO , Jan. 6, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an immuno-oncology company developing proprietary Neukoplast ® , a Natural Killer (NK) cell-line based therapy, announced
View HTML
Toggle Summary Conkwest Appoints Robert Rosen and Henry Ji to its Board of Directors
SAN DIEGO (December 29, 2014) – Conkwest, Inc. (the Natural Killer Cell Company of the West), an immuno-oncology company developing Neukoplast ® , a proprietary Natural Killer (NK) cell-line based therapy, announces the appointments of Robert Rosen and Henry Ji, Ph.D.
View HTML